Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Clinical trial NCT01915498 · COMPLETED
Trial details
- NCT number
- NCT01915498
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-27
- Primary completion
- 2019-07-25
- Enrollment
- 345
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.